Global Cancer Biomarker Market Research Report 2019
Table of Content
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Cancer Biomarker Quarterly Market Size Analysis
- 2.1 Cancer Biomarker Business Impact Assessment - COVID-19
- 2.1.1 Global Cancer Biomarker Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Cancer Biomarker Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 By Players, Global Cancer Biomarker Quarterly Market Size, 2019 VS 2020
- 3.2 By Players, Cancer Biomarker Headquarters and Area Served
- 3.3 Date of Key Players Enter into Cancer Biomarker Market
- 3.4 Key Players Cancer Biomarker Product Offered
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Cancer Biomarker Segments, By Type
- 4.1 Introduction
- 1.4.1 Protein Biomarker
- 1.4.2 Genetic Biomarker
- 4.2 By Type, Global Cancer Biomarker Market Size, 2019-2021
5 Impact of Covid-19 on Cancer Biomarker Segments, By Application
- 5.1 Overview
- 5.5.1 Diagnostics
- 5.5.2 Research
- 5.5.3 Prognostics
- 5.5.4 Risk Assessment
- 5.5.5 Other Applications
- 5.2 By Application, Global Cancer Biomarker Market Size, 2019-2021
- 5.2.1 By Application, Global Cancer Biomarker Market Size by Application, 2019-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Thermo Fisher Scientific
- 7.1.1 Thermo Fisher Scientific Business Overview
- 7.1.2 Thermo Fisher Scientific Cancer Biomarker Quarterly Revenue, 2020
- 7.1.3 Thermo Fisher Scientific Cancer Biomarker Product Introduction
- 7.1.4 Thermo Fisher Scientific Response to COVID-19 and Related Developments
- 7.2 Bio-Rad Laboratories
- 7.2.1 Bio-Rad Laboratories Business Overview
- 7.2.2 Bio-Rad Laboratories Cancer Biomarker Quarterly Revenue, 2020
- 7.2.3 Bio-Rad Laboratories Cancer Biomarker Product Introduction
- 7.2.4 Bio-Rad Laboratories Response to COVID-19 and Related Developments
- 7.3 Roche Diagnostics
- 7.3.1 Roche Diagnostics Business Overview
- 7.3.2 Roche Diagnostics Cancer Biomarker Quarterly Revenue, 2020
- 7.3.3 Roche Diagnostics Cancer Biomarker Product Introduction
- 7.3.4 Roche Diagnostics Response to COVID-19 and Related Developments
- 7.4 Qiagen
- 7.4.1 Qiagen Business Overview
- 7.4.2 Qiagen Cancer Biomarker Quarterly Revenue, 2020
- 7.4.3 Qiagen Cancer Biomarker Product Introduction
- 7.4.4 Qiagen Response to COVID-19 and Related Developments
- 7.5 Illumina
- 7.5.1 Illumina Business Overview
- 7.5.2 Illumina Cancer Biomarker Quarterly Revenue, 2020
- 7.5.3 Illumina Cancer Biomarker Product Introduction
- 7.5.4 Illumina Response to COVID-19 and Related Developments
- 7.6 GE Healthcare
- 7.6.1 GE Healthcare Business Overview
- 7.6.2 GE Healthcare Cancer Biomarker Quarterly Revenue, 2020
- 7.6.3 GE Healthcare Cancer Biomarker Product Introduction
- 7.6.4 GE Healthcare Response to COVID-19 and Related Developments
- 7.7 Agilent Technologies
- 7.7.1 Agilent Technologies Business Overview
- 7.7.2 Agilent Technologies Cancer Biomarker Quarterly Revenue, 2020
- 7.7.3 Agilent Technologies Cancer Biomarker Product Introduction
- 7.7.4 Agilent Technologies Response to COVID-19 and Related Developments
- 7.8 Biomérieux SA
- 7.8.1 Biomérieux SA Business Overview
- 7.8.2 Biomérieux SA Cancer Biomarker Quarterly Revenue, 2020
- 7.8.3 Biomérieux SA Cancer Biomarker Product Introduction
- 7.8.4 Biomérieux SA Response to COVID-19 and Related Developments
- 7.9 Merck & Co.
- 7.9.1 Merck & Co. Business Overview
- 7.9.2 Merck & Co. Cancer Biomarker Quarterly Revenue, 2020
- 7.9.3 Merck & Co. Cancer Biomarker Product Introduction
- 7.9.4 Merck & Co. Response to COVID-19 and Related Developments
- 7.10 Abbott Laboratories
- 7.10.1 Abbott Laboratories Business Overview
- 7.10.2 Abbott Laboratories Cancer Biomarker Quarterly Revenue, 2020
- 7.10.3 Abbott Laboratories Cancer Biomarker Product Introduction
- 7.10.4 Abbott Laboratories Response to COVID-19 and Related Developments
- 7.11 Becton, Dickinson and Company
- 7.11.1 Becton, Dickinson and Company Business Overview
- 7.11.2 Becton, Dickinson and Company Cancer Biomarker Quarterly Revenue, 2020
- 7.11.3 Becton, Dickinson and Company Cancer Biomarker Product Introduction
- 7.11.4 Becton, Dickinson and Company Response to COVID-19 and Related Developments
- 7.12 Danaher Corporation
- 7.12.1 Danaher Corporation Business Overview
- 7.12.2 Danaher Corporation Cancer Biomarker Quarterly Revenue, 2020
- 7.12.3 Danaher Corporation Cancer Biomarker Product Introduction
- 7.12.4 Danaher Corporation Response to COVID-19 and Related Developments
- 7.13 Myriad Genetics
- 7.13.1 Myriad Genetics Business Overview
- 7.13.2 Myriad Genetics Cancer Biomarker Quarterly Revenue, 2020
- 7.13.3 Myriad Genetics Cancer Biomarker Product Introduction
- 7.13.4 Myriad Genetics Response to COVID-19 and Related Developments
- 7.14 Sysmex Corporation
- 7.14.1 Sysmex Corporation Business Overview
- 7.14.2 Sysmex Corporation Cancer Biomarker Quarterly Revenue, 2020
- 7.14.3 Sysmex Corporation Cancer Biomarker Product Introduction
- 7.14.4 Sysmex Corporation Response to COVID-19 and Related Developments
- 7.15 Hologic
- 7.15.1 Hologic Business Overview
- 7.15.2 Hologic Cancer Biomarker Quarterly Revenue, 2020
- 7.15.3 Hologic Cancer Biomarker Product Introduction
- 7.15.4 Hologic Response to COVID-19 and Related Developments
- 7.16 Quest Diagnostics
- 7.16.1 Quest Diagnostics Business Overview
- 7.16.2 Quest Diagnostics Cancer Biomarker Quarterly Revenue, 2020
- 7.16.3 Quest Diagnostics Cancer Biomarker Product Introduction
- 7.16.4 Quest Diagnostics Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
- 9.1 About US
Description
This report covers market size and forecasts of Cancer Biomarker, including the following market information:
Global Cancer Biomarker Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Cancer Biomarker Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Cancer Biomarker Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Cancer Biomarker Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Thermo Fisher Scientific, Bio-Rad Laboratories, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Agilent Technologies, Biomérieux SA, Merck & Co., Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation, Myriad Genetics, Sysmex Corporation, Hologic, Quest Diagnostics, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Protein Biomarker
Genetic Biomarker
Based on the Application:
Diagnostics
Research
Prognostics
Risk Assessment
Other Applications